Sarcopenia: an overview

@article{Marzetti2017SarcopeniaAO,
  title={Sarcopenia: an overview},
  author={Emanuele Marzetti and Riccardo Calvani and Matteo Tosato and Matteo Cesari and Mauro Di Bari and Antonio Cherubini and Agnese Collamati and Emanuela D’Angelo and Marco Pahor and Roberto Bernabei and Francesco Landi and on behalf of the Sprintt Consortium},
  journal={Aging Clinical and Experimental Research},
  year={2017},
  volume={29},
  pages={11-17}
}
Sarcopenia, the age-dependent loss of muscle mass and function, is a common condition among older adults, and is associated with several adverse health outcomes. [...] Key Method A randomized controlled trial will be conducted to evaluate the efficacy of a multi-component intervention for preventing mobility disability and other adverse health outcomes in older adults with PF&S.Expand

Figures and Topics from this paper

Sarcopenia measurement in research and clinical practice.
TLDR
Diagnostic and case finding/screening tools for age-related (primary) sarcopenia used in research and clinical practice are outlined and their ability to reliably predict adverse clinical outcomes and patient responses to potential therapies are examined. Expand
The role of omega-3 in the prevention and treatment of sarcopenia
TLDR
It is concluded that there is growing evidence for a beneficial effect of omega-3 PUFAs supplementation in sarcopenic older persons, which may add to the effect of exercise and/or protein supplementation. Expand
Preserving Mobility in Older Adults with Physical Frailty and Sarcopenia: Opportunities, Challenges, and Recommendations for Physical Activity Interventions
TLDR
The aim of this article is to review age-related physio(patho)logical changes that impact mobility in old age and to provide recommendations and procedures in accordance with the available literature. Expand
Sarcopenia, Currently a Hot Topic: A Narrative Review
TLDR
This study reviewed the recently introduced criteria for the Eastern and Western diagnosis of sarcopenia and included the following: definitions and diagnostic criteria over time; pathophysiology of muscle loss; management especially protein or amino acid supplementation, medications, and physical exercise. Expand
Prevalence of sarcopenia in older women with pelvic floor dysfunction.
  • Rávida R.L. Silva, J. Coutinho, +5 authors Juliana C Maia
  • Medicine
  • European journal of obstetrics, gynecology, and reproductive biology
  • 2021
TLDR
The prevalence of sarcopenia in women with PFD was high and, considering the specific types of these dysfunctions, the prevalence of severe sarc Openia was 50.0% in the women with UI and POP of the anterior and apical wall. Expand
Sarcopenia and health-related outcomes: an umbrella review of observational studies
TLDR
Sarcopenia is associated with several adverse health-related outcomes in older people, and its associations with mortality, disability, and falls are supported by a highly suggestive evidence. Expand
Analysis of Electrical Bioimpedance for the Diagnosis of Sarcopenia and Estimation of Its Prevalence
TLDR
The phase angle, another bioimpedanciometric parameter, emerges which could be a promising risk marker for sarcopenia, since the difference in this between individuals with or without sarc Openia was significant, but its predictive capacity was low and an additional exploration of this topic is required. Expand
Sarcopenia Indicators as Predictors of Functional Decline and Need for Care among Older People
TLDR
High CRi-SMI appeared to indicate good prognosis and less need of care, independently of BMI, andCRi-SF was a more consistent predictor than SF-S MI, which was partly masked by BMI. Expand
Update on mitochondria and muscle aging: all wrong roads lead to sarcopenia
TLDR
An overview of recent findings concerning the interrelation between mitochondrial quality control processes, inflammation and the metabolic regulation of muscle mass in the pathogenesis of sarcopenia is presented highlighting those pathways that may be exploited for developing preventive and therapeutic interventions against muscle aging. Expand
The "BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons" (BIOSPHERE) study: Rationale, design and methods.
TLDR
The rationale, design and methods of the "BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons" study are described as an application of a multi-marker strategy for the development of biomarkers for the newly operationalised Physical Frailty & Sarc Openia condition. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Current nutritional recommendations and novel dietary strategies to manage sarcopenia.
TLDR
The current knowledge on the role of nutrition as a countermeasure for sarcopenia is summarized, the mechanisms of action of relevant dietary agents on the aging muscle are illustrated, and novel nutritional strategies that may help preserve muscle mass and function into old age are introduced. Expand
Understanding sarcopenia as a geriatric syndrome
TLDR
Considering sarcopenia as a geriatric syndrome allows it to be considered as an age-related disease but as a true ‘geriatric syndrome’, to request its recognition and assess its multiple risk factors, and to implement a clinical and public health approach to the management of sarcopenic patients and population at risk. Expand
Sarcopenia risk screening tool: a new strategy for clinical practice.
TLDR
SARC-F may be used as a screening test for sarcopenia in communityliving elderly and has comparable specificity and predictive power for adverse physical outcomes when validated against the criteria developed by American, Asian, and European consensus panels. Expand
Treating sarcopenia in older and oldest old.
TLDR
Evidence is provided regarding the effects of different physical exercise protocols, specific nutritional intervention, and some new metabolic agents (HMB, citrulline malate, ornithine, and others) on clinical outcomes related to sarcopenia in older adults. Expand
Exercise as a remedy for sarcopenia
TLDR
Regular exercise is the only strategy found to consistently prevent frailty and improve sarcopenia and physical function in older adults. Expand
The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates
TLDR
Based on the analyses presented in this series, the final recommended cutpoints for weakness are grip strength <26kg for men and <16kg for women, and for low lean mass, appendicular lean mass adjusted for body mass index <0.789 forMen and women. Expand
Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials.
TLDR
This review summarizes prominent findings and controversial issues on the contribution of specific mitochondrial processes - including oxidative stress, quality control mechanisms and apoptotic signaling - on the development of sarcopenia and presents methodological and safety considerations for the design of clinical trials targeting mitochondrial dysfunction to treat sarc Openia. Expand
Frailty, Physical Frailty, Sarcopenia: A New Conceptual Model.
TLDR
A novel conceptualisation of PF is presented which will possibly promote significant advancements over the traditional approaches to this syndrome by enabling the precise operationalisation of the condition, a clear identification of the affected population and the rapid translation of findings to the clinical arena. Expand
Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
TLDR
A set of potential endpoints and target population definitions are suggested to stimulate debate and progress within the medico-scientific and regulatory communities to help facilitate the delivery of effective medicines to patients at risk of sarcopenia. Expand
Sarcopenia, sarcopenic obesity and mortality in older adults: results from the National Health and Nutrition Examination Survey III
TLDR
Older women with sarcopenia have an increased all-cause mortality risk independent of obesity, and this group is a high-risk group with both disorders. Expand
...
1
2
3
4
5
...